Clinical trials: MACULAR EDEMA
Diabetic Macular Edema
Multicentre Randomised Clinical Trial Comparing Fixed vs Pro re Nata (PRN) Dosing of 700 μg Dexamethasone
Multicentre randomized controlled trial to evaluate whether 5 monthly fixed dosing of 700 µg Dexamethasone Posterior Segment Drug Delivery System (Ozurdex) is as efficacious as Optical coherence tomography (OCT)-guided PRN dosing…
- Trial name
- OZDRY (NCT01892163)
- Testing
- Ozurdex
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Moorfields Eye Hospital NHS Foundation Trust
Diabetic Macular Edema
Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema
The purpose of this study is to determine the efficacy of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) on the best corrected visual acuity (BCVA) assessed by the early treatment diabetic retinopathy study (ETDRS)…
- Trial name
- VISTA DME (NCT01363440)
- Testing
- Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321), Macular Laser Photocoagulation
- Where
- 51 sites in United States
- Volunteers
- 466 people
- Sponsor
- Regeneron Pharmaceuticals
Macular Edema, Retinal Vein Occlusion
An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2)
This is an open-label, multicenter, extension study of intravitreally administered ranibizumab in two cohorts. The first cohort (reported separately under FVF3426g, NCT00379795) enrolled subjects with primary or recurrent…
- Trial name
- NCT01442064
- Testing
- Ranibizumab 0.5 mg
- Volunteers
- 608 people
- Sponsor
- Genentech, Inc.
Macular Edema, Branch Retinal Vein Occlusion
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion
This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled, parallel-group study evaluating the efficacy, safety, and pharmacokinetics of faricimab administered by intravitreal (IVT) injection at…
- Trial name
- BALATON (NCT04740905)
- Testing
- Faricimab, Aflibercept
- Where
- 150 sites in United States, Argentina and 20 more
- Volunteers
- 553 people
- Sponsor
- Hoffmann-La Roche
Macular Edema Secondary to Branch Retinal Vein Occlusion
Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)
Provided efficacy and safety data on intravitreal injections of ranibizumab 0.5 mg in patients with visual impairment due to macular edema secondary to BRVO
- Trial name
- Blossom (NCT01976338)
- Testing
- Ranibizumab 0.5 mg
- Where
- 33 sites in China, Hong Kong and 4 more
- Volunteers
- 283 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema
Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs Aflibercept in Patients With DME
This study is designed to compare the post injection inflammation and pain seen after intravitreal injections of ranibizumab 0.3mg and aflibercept 2.0mg in patients with DME.
- Trial name
- NCT02363621
- Testing
- Ranibizumab 0.3 mg, Aflibercept 2.0 mg
- Where
- United States
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Arshad Khanani
Diabetic Macular Edema
Ranibizumab and Bevacizumab for Diabetic Macular Edema
Background: Diabetic macular edema is a common eye complication of diabetes. It causes the blood vessels in the retina at the back of the eye to leak, causing swelling.
- Trial name
- NCT01610557
- Testing
- Ranibizumab, Bevacizumab
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 56 people
- Sponsor
- National Eye Institute (NEI)
Macular Edema
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Participants With Diabetic Macular Edema
The study will be composed of 3 periods for all participants: Screening, 28-day Treatment period, and Follow-up visit (approximately 28 days after the final dose).
- Trial name
- NCT04292912
- Testing
- GSK2798745
- Where
- 11 sites in United States, Australia and 1 more
- Volunteers
- 16 people
- Sponsor
- GlaxoSmithKline
Diabetic Macular Edema
A Single Ascending Dose Cohort Study of AG-73305 in DME Patients
This is a multi-centered, open-labeled, single ascending-dose-cohort study to evaluate the safety and efficacy of 4 dose cohorts of AG-73305 administered by intravitreal injection in patients with diabetic macular edema (DME).
- Trial name
- NCT05301751
- Testing
- AG-73305
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- Allgenesis Biotherapeutics Inc.
Macular Edema, Retinal Vein Occlusion
A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO)
This was a Phase III, multicenter, randomized, double-masked, sham injection-controlled study of the efficacy and safety of intravitreal ranibizumab compared with sham injections in patients with macular edema secondary to branch…
- Trial name
- BRAVO (NCT00486018)
- Testing
- Ranibizumab injection 0.3 mg, Ranibizumab injection 0.5 mg
- Volunteers
- 397 people
- Sponsor
- Genentech, Inc.
Diabetic Macular Edema (DME)
Observational Study to Assess the Effect of Iluvien® in DME Patients Insufficiently Responsive to Available Therapies
This observational study aims to assess the safety and effect of Iluvien® in DME patients considered insufficiently responsive to available therapies in a real life setting in Germany.
- Trial name
- ILUMINATE (NCT02080091)
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- Alimera Sciences
Post-surgical Cystoid Macular Edema (PSCME)
Treatment of Post-surgical Cystoid Macular Edema With Topical Steroids Trial (TEMPEST-1)
The purpose of this study is to compare the change in visual acuity of patients with post surgical cystoid macular edema who will be treated with two different regimens.
- Trial name
- TEMPEST (NCT01769352)
- Testing
- PredA + Kelac
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Johns Hopkins University
Macular Edema, Retinal Vein Occlusion
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO
This Phase 3, multicenter, randomized, masked, controlled, parallel group study is designed to demonstrate that suprachoroidal (SC) CLS-TA administered with intravitreal (IVT) anti-VEGF agent in subjects with treatment naive RVO…
- Trial name
- TOPAZ (NCT03203447)
- Testing
- suprachoroidal CLS-TA, Lucentis or Avastin
- Where
- 92 sites in United States, Australia and 3 more
- Volunteers
- 325 people
- Sponsor
- Clearside Biomedical, Inc.
Diabetic Macular Edema
Ranibizumab and Peripheral Scatter Laser in Patients With Diabetic Macular Edema and Peripheral Nonperfusion
To investigate the role of ranibizumab and angiographically-directed peripheral scatter laser therapy in patients with clinically-significant diabetic macular edema (CSME) and peripheral nonperfusion.
- Trial name
- RaScaL (NCT00815360)
- Testing
- intravitreal injection of ranibizumab, peripheral laser, intravitreal injection of triamcinolone acetonide
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Retina Associates of Florida, P.A.
Retinal Vein Occlusion, Macular Edema
A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema
This retrospective data review study will evaluate anti-VEGF injections for retinal vein occlusion (RVO) or diabetic macular edema (DME).
- Trial name
- NCT01918371
- Testing
- Anti-VEGF
- Where
- United States
- Volunteers
- 323 people, healthy volunteers welcome
- Sponsor
- Allergan
Macular Edema Secondary to Retinal Vein Occlusion
A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)
Researchers are looking for a better way to treat people who have macular edema secondary to retinal vein occlusion (RVO). In people with RVO, a blood vessel that carries blood away from the retina (vein) becomes blocked.
- Trial name
- QUASAR (NCT05850520)
- Testing
- Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Fluorescein
- Where
- 273 sites in United States, Australia and 25 more
- Volunteers
- 892 people
- Sponsor
- Bayer
Diabetic Macular Edema
Chart Review: Drug Utilization Study in Participants Who Received Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Visual Impairment Due to Diabetic Macular Edema (DME)
A retrospective, non-interventional, observational, multi-center, drug utilization study to be conducted in adult participants with visual impairment due to DME treated with Ozurdex implants in Germany and Switzerland from 1…
- Trial name
- NCT03889444
- Testing
- Dexamethasone intravitreal implant
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- Allergan
Diabetic Macular Edema
Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema
This study is designed to demonstrate the safety and tolerability of suprachoroidal CLS-TA alone or in combination with intravitreal aflibercept in subjects with diabetic macular edema associated with diabetes mellitus.
- Trial name
- HULK (NCT02949024)
- Testing
- IVT Aflibercept, SC CLS-TA
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Clearside Biomedical, Inc.
Diabetic Macular Edema, Hard Lipid Exudates
The Effect of Intravitreal Ranibizumab on Visual Acuity and Hard Exudate Resolution in the Treatment of Diabetic Macular Edema With Center Involved Edema and Lipid Exudates
This is an open-label, Phase I/II study of intravitreally administered 0.3mg ranibizumab in subjects with diabetic macular edema and lipid exudates in the central subfield.
- Trial name
- NCT02448446
- Testing
- ranibizumab 0.3mg
- Where
- 4 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- South Coast Retina Center; Carson, McBeath, Boswell, Inc.
Macular Edema
A Safety and Efficacy Study of Dexamethasone Versus Laser Photocoagulation in Participants With Diabetic Macular Edema
This study will evaluate the safety and efficacy of 700 μg dexamethasone versus laser photocoagulation in participants with diabetic macular edema (DME).
- Trial name
- NCT02121262
- Testing
- Dexamethasone, Laser Photocoagulation
- Where
- 18 sites in China, Philippines
- Volunteers
- 284 people
- Sponsor
- Allergan